Research programme: therapeutic antibody fragments - Cell Medica

Drug Profile

Research programme: therapeutic antibody fragments - Cell Medica

Alternative Names: DLX-1008; DLX-212; DLX-2201; DLX-2323/DLX2681; DLX-2751; DLX-2882/3003; DLX-521; DLX-903; DLX-903/1008

Latest Information Update: 12 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Delenex Therapeutics
  • Developer Cell Medica
  • Class Antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors; Anaplastic lymphoma kinase inhibitors; Interleukin 1 beta inhibitors; Interleukin 12 inhibitors; Interleukin 23 inhibitors; Interleukin-17 inhibitors; Tumour necrosis factor alpha inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acne; Cancer; Glioblastoma; Gout; Hidradenitis suppurativa; Inflammatory bowel diseases; Kaposi's sarcoma; Neurological disorders; Psoriasis; Pyoderma; Skin disorders

Most Recent Events

  • 12 Jul 2016 Delenex Therapeutics has been acquired and merged into Cell Medica
  • 07 Oct 2015 Preclinical trials in Acne in Switzerland (SC)
  • 07 Oct 2015 Preclinical trials in Acne in Switzerland (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top